Next Generation Tissue Biomarkers Market Size, Share & Trends Analysis Report By Product (Reagents & Assays, Instruments & Platforms), By Type (Genomic, Proteomic), By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global next generation tissue biomarkers market size was estimated at USD 3.02 billion in 2024 and is projected to grow at a CAGR of 12.74% from 2025 to 2030. Next-generation tissue biomarkers are essential for advancing personalized medicine and play a crucial role in identifying disease conditions as in cardiovascular, chronic diseases, cancer, and several infections. Key driving factors such as the increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicine are responsible for market growth.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. For instance, in November 2024, Illumina, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its in vitro diagnostic (IVD) TruSight Oncology Comprehensive test, marking a significant advancement in precision oncology. This test analyzes over 500 genes in solid tumor samples to identify biomarkers that can guide targeted therapy decisions. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. This would enhance the discovery of new morphological biomarkers and improve diagnostic efficiency.

Growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients. These biomarkers, detectable through innovative tissue analysis techniques, provide insights into tumor characteristics, guiding therapeutic decisions. In August 2024, Paige, a company in next-generation AI technology, introduced OmniScreen, an advanced AI-driven biomarker module capable of evaluating over 505 genes and detecting 1,228 molecular biomarkers. Paige's OmniScreen represents a significant advancement in personalized medicine, offering detailed insights into cancer biology and potential treatment avenues, thereby improving patient outcomes. In addition,in November 2024, Tempus AI, Inc., a company in AI-driven precision medicine, announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. This multimodal biomarker serves as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors. Thus, incorporating next-generation tissue biomarker analysis into clinical practice represents a significant stride toward personalized medicine, offering the potential for more accurate diagnoses and individualized treatment plans.

Market Opportunities for Next Generation Tissue Biomarkers in Tissue Diagnostics

The market for next-generation tissue biomarkers in disease diagnosis is experiencing significant growth, driven by advancements in precision medicine, digital pathology, and biomarker discovery technologies. These developments are enhancing early disease detection, personalized treatment strategies, and overall patient outcomes.

Market Concentration & Characteristics

The next generation tissue biomarkers industry is marked by a high degree of innovation, by enhancing diagnostic accuracy, enabling personalized treatments, and improving patient outcomes. In April 2025,ViewsML and Dartmouth Health partnered, aiming at advancing AI-driven virtual biomarkers and diagnostics. This collaboration focuses on developing virtual biomarkers through ViewsML's virtual immunohistochemistry (IHC) staining platform, which reduces reliance on traditional physical antibodies and immunostaining methods.

The next generation tissue biomarkers industry has experienced notable fluctuations over the past few years, influenced by technological advancements, market dynamics, and strategic shifts within the medical sector. According to an article from January 2025, Quanterix Corporation announced to acquire Akoya Biosciences in an all-stock transaction, aiming to create the first integrated solution for ultra-sensitive detection of both blood- and tissue-based protein biomarkers. This merger positions the combined entity to lead the biomarker detection field, offering integrated solutions that span both blood and tissue analyses.

Regulations play a crucial role in shaping the next generation tissue biomarkers industry, affecting product approvals, market adoption, and innovation. Regulatory bodies such as the FDA (U.S.), CE Mark (Europe), and CFDA (China) enforce strict guidelines to ensure diagnostic accuracy, patient safety, and data security.

The next-generation tissue biomarkers have significantly advanced disease diagnosis and monitoring. Several alternative diagnostic methods offer complementary or substitute options, such as proteomics, circulating free DNA analysis, and liquid biopsies. These alternatives provide diverse approaches to disease diagnosis and monitoring, each with its own set of advantages and limitations. The choice of method depends on the specific clinical context, the disease in question, and the desired information to be obtained.

The next generation tissue biomarkers industry exhibits a high level of end use concentration, primarily driven by demand from hospitals and reference labs, pharma and biotech companies, academic and research institutions, and contract research organizations. Large healthcare networks and academic medical centers account for a significant portion of adoption, as they require high-throughput scanning and AI-powered diagnostics. Reference laboratories and contract research organizations (CROs) also contribute to market growth by utilizing digital pathology for clinical trials. While adoption is growing in smaller pathology labs, the market remains concentrated among large-scale institutions with higher diagnostic volumes and technology budgets.

New Technology and Adoption Landscape of Next Generation Tissue Biomarkers

The next generation tissue biomarkers industry in tissue diagnostics is undergoing rapid transformation, driven by advancements in AI, whole slide imaging (WSI), telepathology, and automation. These innovations are improving diagnostic accuracy, workflow efficiency, and accessibility, leading to increased adoption across hospitals, research institutions, and diagnostic laboratories.

New Technology and Adoption Landscape of New Generation Tissue Biomarkers

Advanced genomic profiling: The landscape of next-generation tissue biomarkers has significant advancements in precision medicine, genomics, and diagnostics:-

• Next-Generation Sequencing (NGS):-These platforms provide comprehensive insights into genomic mutations, gene expression patterns, and epigenetic alterations in tumors or other tissues.

Example: FoundationOne by Foundation Medicine.

• Single-Cell RNA Sequencing (scRNA-seq):-This technology allows the profiling of individual cells within a tissue sample, offering detailed insights into cell-specific molecular signatures.

Example:-10x Genomics offers platforms for single-cell RNA sequencing

• Spatial Transcriptomics:- Spatial transcriptomics provides detailed information about how genes are regulated within specific regions of a tissue sample. It offers a new layer of insight into tissue heterogeneity

Example:-Spatial Transcriptomics by 10x Genomics is a technology that maps gene expression patterns to tissue sections.

• Liquid biopsy: It is a non-invasive emerging technology that allows for the detection of tissue-specific biomarkers from blood, urine, or other bodily fluids. It is particularly useful for detecting cancer-related mutations, monitoring disease progression, and predicting therapeutic responses.

Example:-Guardant360 by Guardant Health is a liquid biopsy test that detects genetic mutations in tumor DNA found in the blood.

• Artificial Intelligence and Machine Learning (AI/ML): By processing vast amounts of tissue biomarker data, AI can accelerate the identification of clinically relevant biomarkers that can inform personalized treatment approaches.

• Example: PathAI is a company using AI to help pathologists interpret tissue slides.

Adoption Trends:

• High adoption in personalized medicine.

• Increasing demand for clinical diagnostics.

• Rising market growth and investments

Product Insights

The reagents and assays accounted for the largest revenue share of 55.97% in 2024. This segment is expected to witness rapid expansion due to its broad applicability in biopharmaceutical research. These kits are crucial for studying various cellular behaviors, including cell cycle progression, movement, and infiltration. Additionally, they are instrumental in measuring key cellular components, which are often used to evaluate cell viability and responses to various stimuli. The increasing prevalence of cancer and other tissue-related diseases has accelerated the demand for faster and more precise diagnostic solutions, leading to the widespread adoption of reagents and assays. A key driving factor is the growing need for early disease detection and diagnostics, which has resulted in high demand for accurate, reliable, and rapid diagnostics, contributing to market growth. Advancements in technologies like next-generation sequencing (NGS), CRISPR, and digital PCR have enhanced the capability and applications of reagents and assays.

For example, in September 2024, QIAGEN reached a significant milestone with the introduction of 100 new assays for its QIAcuity digital PCR (dPCR) platform, designed to advance research in cancer, inherited genetic disorders, and infectious disease monitoring. QIAcuity is emerging as an essential tool for a wide variety of applications that demand precise and sensitive detection of genetic targets, fueling the advancement of new multiplexed assay. The newly introduced assays consist of dPCR LNA (locked nucleic acid) Mutation, dPCR CNV (copy number variation) Probe Assays, and dPCR Microbial DNA Detection Assays. The device will facilitate applications like diagnosing infectious diseases and tracking cancer progression and treatment responses through less invasive liquid biopsy methods.

Type Insights

The genomic biomarker segment dominated the market, capturing a 32.18% revenue share in 2024 owing to the rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments. For instance, in June 2024, BioAI and the Genomic Testing Cooperative announced a strategic collaboration to deliver AI-driven digital pathology solutions for clinical research and diagnostic applications. The collaboration’s goals include developing genomic biomarkers, screening algorithms, and assays, with plans to deploy them in clinical environments. In addition, in August 2024, Illumina, Inc., a global company in DNA sequencing and array-based technologies, announced that its TruSight Oncology (TSO) Comprehensive test received approval from the U.S. Food and Drug Administration (FDA) as an in vitro diagnostic (IVD) tool. Regulatory support, patient awareness, and bioinformatics advancements are all playing pivotal roles in accelerating the use of genomic biomarkers in clinical and research settings.

Metabolomic biomarkers are expected to grow at the fastest CAGR over the forecast period. Metabolomic biomarkers refer to specific metabolic changes or substances in the body that can be measured and used to identify disease states, predict disease risk, and monitor responses to treatments. The rising interest in understanding metabolic changes associated with prostate cancer is driving the growth of this segment. For example, in February 2025, Metabolon, Inc. announced new multiomics biomarker discovery features within its newly launched Integrated Bioinformatics Platform. These enhancements include multiomics predictive modeling, latent factor analysis, multiomics pathway analysis using public tools like Reactome, and advanced data visualization capabilities for multiomic datasets. Metabolomic biomarkers provide insights into disease mechanisms by analyzing small molecule profiles in biofluids such as urine, serum, and plasma. These markers support early detection and offer the potential for distinguishing aggressive from indolent cancer forms. Advances in analytical techniques like NMR spectroscopy and mass spectrometry have improved the detection and quantification of metabolic changes. Growing investments in precision oncology and increasing use of metabolomics in research and clinical trials are further accelerating the segment’s expansion.

Technology Insights

The next generation sequencing segment dominated the market with the largest revenue share of 28.97% in 2024. Next Generation Sequencing (NGS) refers to the huge DNA sequencing methods that aid in genomic discovery. In February 2025, Roche introduced its groundbreaking sequencing by expansion (SBX) technology, creating a new category within next-generation sequencing. By combining SBX chemistry with an advanced sensor module, this technology enables ultra-fast, high-throughput sequencing that is versatile and scalable, suitable for a wide array of applications. This innovation establishes a new category in next-generation sequencing, offering substantial improvements over existing technologies. In addition, in May 2023, Pfizer and Thermo Fisher Scientific Inc. announced a collaboration to expand local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia, where advanced genomic testing has previously been scarce or inaccessible.

Spatial genomics biology segment is anticipated to witness a lucrative CAGR of 15.97% from 2025 to 2030. The advancements in genome editing tools, such as the CRISPR/Cas9 system, have facilitated spatial genomics biology adoption, driving market growth. For example, in February 2025, Bruker Corporation announced major innovations in spatial biology, including the Whole Transcriptome Panel (WTX), the PaintScape platform for direct 3D genome visualization, the CellScape PowerOMX software engine, and the GeoMx protein panel. PaintScape offers researchers an in-depth view of the 3D genome, enabling them to explore how structural variations in the genome influence gene expression and contribute to disease mechanisms. Furthermore, in January 2024, Bio-Techne Corporation revealed that Advanced Cell Diagnostics (ACD), a spatial biology brand under Bio-Techne, established a new benchmark with the introduction of a next-generation, protease-free RNAscope spatial multiomics workflow. This newly developed workflow is compatible with both manual and automated assays. By enabling the simultaneous imaging of RNA and protein biomarkers on the same tissue section, it offers an unparalleled single-cell perspective on disease pathology and therapeutic response. Moreover, the potential of spatial genetics analysis has increased investments in the innovation of new products in the healthcare sector, which is further propelling growth opportunities in the market.

Application Insights

The oncology segment dominated the market with the largest revenue share of 60.18% in 2024. The growing demand for precision medicine drives the segment growth and targeted cancer therapies. Next generation tissue biomarkers are essential in identifying cancer subtypes, predicting treatment responses, and monitoring therapeutic efficacy. In April 2024, Takara Bio USA, Inc., a fully owned subsidiary of Takara Bio Inc., revealed the launch of the Shasta Single-Cell System, an automated, high-throughput NGS solution. Takara Bio USA already provided instruments and NGS kits to early-access users. This comprehensive system enables researchers to extract a greater volume of genomic and transcriptomic data from far more cells than current technologies allow, all while reducing time and costs for research teams. The increasing prevalence of cancer, along with advancements in immuno-oncology, has heightened the need for innovative next generation tissue biomarkers.

Companion diagnostics are expected to grow at the fastest CAGR of 15.49% over the forecast period. The companion diagnostics segment is experiencing significant product expansion, with new assays being developed for various cancer types, autoimmune diseases, and neurological disorders. Companies are focusing on multiplex diagnostics, which allow simultaneous testing of multiple biomarkers. Rising healthcare investments, improved regulatory frameworks, and growing awareness of precision medicine are driving expansion. For example, in January 2025, Foundation Medicine, Inc. announced that the U.S. Food and Drug Administration (FDA) approved FoundationOneCDx as a companion diagnostic for Day One Biopharmaceuticals' OJEMDA, a treatment for patients aged six months and older. FoundationOne CDx is the first and only companion diagnostic for OJEMDA. The FDA-approved test analyzes more than 300 cancer-related genes in a patient's tumor using a tissue sample. Advancements in biomarker discovery and targeted therapies further contribute to the expansion of this segment, enabling healthcare providers to tailor treatments to individual patient profiles, thereby improving outcomes and reducing adverse effects.

End-use Insights

The hospitals & reference labs segment dominated the end use segments with the largest market share of 41.18% in 2024. Hospitals and reference labs are rapidly adopting next generation tissue biomarkers to enhance efficiency, accuracy, and accessibility. With the rising global burden of cancer and other tissue-related diseases, hospitals require faster, high-throughput solutions to manage increasing case volumes. In March 2021, Hackensack Meridian Health, a reference lab, and the Genomic Testing Cooperative (GTC) in California partnered to create a groundbreaking genomic profiling laboratory named Anthology Diagnostics. This lab aims to provide more personalized, precise, and real-time insights for cancer patients, oncologists, and hospitals. This reference lab will offer next-generation sequencing data for both DNA and RNA, which will aid clinicians in making treatment decisions and support researchers in discovering innovative biomarkers to enhance the understanding and management of blood cancers and solid tumors. For instance, in May 2023, NHS Borders launched its Rapid Cancer Diagnostic Service (RCDS), a significant step forward in early detection for patients presenting with vague or nonspecific symptoms. This initiative exemplifies the growing commitment among hospitals to integrate cutting-edge companion diagnostic solutions to improve patient outcomes. The evolution of hospital laboratories is pivotal in meeting changing patient needs, prompting healthcare facilities to broaden their service offerings. In addition, hospitals are investing in advanced diagnostic platforms and forging collaborations with pharmaceutical companies to bolster their personalized cancer care capabilities.

Contract research organizations are projected to grow at a CAGR of 15.19% during the forecast period. These organizations are heavily involved in research and development, focusing on targeted therapies that require precise biomarker identification. These organizations, which provide outsourced research services to the pharmaceutical, biotechnology, and medical device industries, are at the forefront of integrating advanced biomarker technologies into clinical trials and translational research.

Regional Insights

North America next generation tissue biomarker industry dominated globally with a revenue share of 46.14% in 2024. This large share is primarily attributed to advanced healthcare infrastructure, substantial healthcare expenditure, and a robust regulatory framework that expedites approvals for new generation tissue biomarkers. Technological advancements in medical research and development are also contributing to market expansion. These innovations improve the quality and speed of diagnostic processes, making new generation tissue biomarkers more appealing to healthcare providers. Leading research institutions and biotech firms across the region are driving innovation through the development of cutting-edge diagnostic methods. In addition, the growing prevalence of chronic diseases, including cancer, necessitates advanced technologies, further propelling the demand for new generation tissue biomarkers. In January 2025, Quanterix Corporation, a company in ultra-sensitive biomarker detection, and Akoya Biosciences, known for its spatial biology expertise, announced a definitive agreement in which Quanterix will acquire Akoya. The merger will create the first integrated solution for the ultra-sensitive detection of both blood- and tissue-based protein biomarkers, enabling early disease detection through non-invasive methods, even before symptoms manifest.

U.S. New Generation Tissue Biomarker Market Trends

The new generation tissue biomarker industry in the U.S. is projected to witness significant market expansion, driven by the high prevalence of chronic diseases (including cancer) and the rapid adoption of advanced diagnostic solutions. Ongoing technological advancements, frequent FDA approvals for novel tests, and growing competition among biotechnology companies further bolster market growth prospects in the country.

Europe New Generation Tissue Biomarker Market Trends

The Europe next generation tissue biomarkers industry commands a notable share of the global companion diagnostics market, supported by developed economies such as Germany, Spain, the UK, France, and Italy. In November 2023, GenDx, a Eurobio Scientific Company, announced a partnership with OSE Immunotherapeutics, a French biotech company focused on developing first-in-class immuno-oncology treatments, to create and validate a companion diagnostic (CDx) test. This marks GenDx's first move into the companion diagnostic market, coinciding with the opening of their new offices at the Utrecht Science Park. These nations benefit from strong healthcare infrastructure and robust clinical research capabilities, spurring market growth. In the UK, advanced healthcare systems, strategic partnerships, and the introduction of innovative products drive adoption. Meanwhile, France’s focus on in-house genomic testing and Germany’s rising disease incidence also contribute to market expansion. Overall, these factors position Europe for sustained growth in next generation tissue biomarkers.

The UK next generation tissue biomarkers industry is experiencing significant growth, driven by advanced healthcare infrastructure, strategic collaborations, and a strong focus on precision medicine. Increased investments in innovative technologies and strong regulatory support facilitate the development of cutting-edge tests for personalized therapies.

In September 2024, Biofidelity, a pioneer in cutting-edge genomic solutions, announced the opening of a new manufacturing facility in the UK dedicated to the production of genomic assays. This new facility is dedicated to the production of high-quality genomic assays, reinforcing Biofidelity’s commitment to advancing genomic research and diagnostics. Partnerships between hospitals and reference labs boost research efforts, enhancing diagnostic accuracy and treatment outcomes. With an emphasis on early detection and care, the UK market is poised for continued expansion and greater integration of companion diagnostic solutions.

Asia Pacific New Generation Tissue Biomarker Market Trends

Asia Pacific next generation tissue biomarkers industry is anticipated to witness the fastest CAGR over the forecast period. The Asia-Pacific market is experiencing significant growth, propelled by healthcare reforms, infrastructure enhancements, and a large patient pool. The region’s high burden of chronic diseases, including cancer, underscores the need for effective biomarker detection solutions. In September 2023, Agilent Technologies Inc. entered into a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) to advance translational cancer research focused on the genomic landscape of cancers prevalent in Asia. As part of the agreement, Agilent will supply the Magnis Next-Generation Sequencing (NGS) Preparation System to assist in studying specific details related to Asian cancer cohorts, where tissue samples from routine clinical care are often limited both locally and regionally. The collaboration aims to deliver consistent results by streamlining the analysis of multiple genes and complex genetic alterations from genomic DNA.

The next generation tissue biomarkers industry in China is experiencing significant growth, driven by a rising prevalence of chronic diseases and an increasing focus on precision medicine. Significant investments in research and development, along with favorable government policies, have accelerated the adoption of advanced diagnostic technologies.

Latin America New Generation Tissue Biomarker Market

Latin America next generation tissue biomarkers industry offers lucrative opportunities in the companion diagnostics space, driven by the rapid advancement of precision medicine and various R&D initiatives. Collaborations between pharmaceutical companies, diagnostic firms, and service providers are improving access to cutting-edge testing technologies. In September 2024, Biocare Medical, a company in immunohistochemistry (IHC) instrumentation and reagents, partnered with Ensigna Biosystems, a leading provider of advanced histopathology services, and announced a new strategic collaboration. This partnership aimed to expand and enhance innovative spatial biology applications, which are crucial for advancing biomedical research and the development of therapies. These partnerships between global innovators and local healthcare providers continue to reinforce Latin America’s standing as a promising region for new generation tissue biomarker

Middle East and Africa New Generation Tissue Biomarker Market Trends

The Middle East and Africa (MEA) new generation tissue biomarker industry is expanding due to improving healthcare infrastructure, rising prevalence of chronic diseases, and growing adoption of AI-ML. Although many areas remain underpenetrated due to limited screening programs. Governments are increasingly focusing on expanding early detection efforts and promoting noninvasive diagnostic methods.

Key Next Generation Tissue Biomarkers Company Insights

Some of the key players operating in the market include Roche Diagnostics/Ventana Medical Systems, Agilent Technologies/Dako, Thermo Fisher Scientific, and among others. New product launch, mergers and acquisitions, and collaborations are some of the major strategies adopted by these players to counter the stiff competition.

Recent Developments

• In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.

• In February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing, while also providing gene expression data.

• On September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.

Next Generation Tissue Biomarkers Market Report Scope

Global Next Generation Tissue Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global next generation tissue biomarkers market report based on product, application, technology, type, end-use, and region

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Reagents & Assays

  • Instruments & Platforms

  • Software & AI

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Genomic Biomarkers

  • Proteomic Biomarkers

  • Epigenetic Biomarkers

  • Transcriptomic Biomarkers

  • Metabolomic Biomarkers

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Immunohistochemistry

  • Next-generation Sequencing (NGS)

  • Mass Spectrometry (MS)-based Proteomics

  • Spatial Biology Platforms

  • Digital Pathology & AI Analysis

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology

  • Companion Diagnostics

  • Drug Discovery & Development

  • Neurology

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Reference Labs

  • Pharma & Biotech Companies

  • Academic & Research Institutes

  • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait